The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased intraocular pressure.
We evaluated the efficacy and safety of latanoprost eye drops once-weekly, compared to once-daily for improving patient compliance. Twenty (20) patients (11 women and 9 men), 12 with ocular hypertension and 8 with early glaucoma, were studied after washout of the antiglaucoma treatment. One (1) group was treated with latanoprost once-daily (control). The other group was treated once-weekly (study group). Intraocular pressure (IOP) was measured at baseline and on the 2nd, 4th, 6th, and 9th day after the last drop in the study group, and for 3 months on the same schedule thereafter. The mean baseline IOP was 24.3 +/- 3.9 mmHg in the study group (range, 18-29) and 24.4 +/- 4.4 mmHg in the control group (range, 17-32). The average IOP at all time points of post-treatment was 17.7 +/- 1.5 mmHg (range, 14-23) and 16.9 +/- 2.30 mmHg (range, 13-21), respectively. Latanoprost significantly lowered IOP in both groups (study group, p = 0.005; controls, p = 0.0019). The difference between post-treatment IOP was insignificant in both groups at each time point. The study group had fewer minor side effects than the control group (1/10 versus 6/10, respectively). Latanoprost treatment once-weekly was as effective, and bore fewer minor side effects, as once-daily treatment after 3 months of follow-up.
Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. kurtzs@inter.net.il
Shimon
S
Kurtz
Gabi
G
Shemesh
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D004334:Drug Administration Schedule; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects* / Q000502:physiology; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D010349:Patient Compliance; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects*; D011537:Pruritus / Q000139:chemically induced; D018709:Statistics, Nonparametric
D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost